Skip to main content
. 2018 Nov 5;124(22):4342–4349. doi: 10.1002/cncr.31706

Table 3.

Most Frequently Reported Grade 3 or 4 Adverse Events: Daratumumab, N = 348a

Adverse Event No. of Patients (%)
Grade 3 or 4 adverse event 175 (50)
Drug‐related 85 (24)
Thrombocytopenia 53 (15)
Anemia 47 (14)
Neutropenia 28 (8)
Lymphopenia 22 (6)
Hypercalcemia 17 (5)
a

These were adverse events reported in ≥1% of patients.